Radionuclide neuroendocrine tumors functional imaging

3,787 views

Published on

Overview of radionuclide functional imaging of NET

Published in: Health & Medicine
1 Comment
5 Likes
Statistics
Notes
No Downloads
Views
Total views
3,787
On SlideShare
0
From Embeds
0
Number of Embeds
9
Actions
Shares
0
Downloads
223
Comments
1
Likes
5
Embeds 0
No embeds

No notes for slide

Radionuclide neuroendocrine tumors functional imaging

  1. 1. Radionuclide Functioning Imaging of Neuroendocrine Tumors (NET) Hussein Farghaly, MD Assistant Prof. and Consultant of Nuclear Medicine Assiut University-Egypt 2014
  2. 2. Neuroendocrine tumors • NET are derived from embryonic neural crest tissue found in the hypothalamus, pituitary gland, thyroid gland, adrenal medulla, and gastrointestinal tract. • NET´s belong to the so called amine precursor uptake and decarboxylation (APUD)- omas • Generally more indolent than adenocarcinoma of the same site. • Capable of producing hormonal syndrome (i.e. carcinoid syndrome) – WHO classification • Well differentiated neuroendocrine tumor • Well differentiated neuroendocrine carcinoma • Poorly differentiated neuroendocrine carcinoma
  3. 3. Neuroendocrine tumors most commonly encountered in clinical practice - Enteropancreatic tumors (carcinoid tumors, gastrinoma, glucagonoma, vasoactive intestinal peptide [VIP]–related tumors [VIPomas] – Poorly differentiated neuroendocrine tumors – Sympathoadrenal tumors (pheochromocytoma [PHEO], neuroblastoma, paraganglioma) – Multiple endocrine neoplasia (MEN) syndromes (type 1 MEN, type 2 MEN) – Medullary thyroid carcinoma (MTC).
  4. 4. Radiopharmaceuticals • Radiopharmaceuticals used for imaging neuroendocrine tumors are either similar in molecular structure to the hormones synthesize or incorporated into various metabolic and cellular processes of the tumor cells. • Somatostatin Analogs (111-In DTPA /99mTc-Octreotide, Ga68-DOTA) • Catecholamine Analogs and metabolities (131I/123I- MIBG,18F/11C-DOPA, 11C-HTP, 11C-HED) • Glucose Analog (18F-FDG)
  5. 5. Indication Of NETs Radionuclide Imaging
  6. 6. Somatostatin Analogues • Neuroendocrine tumors (NETs) express multiple somatostatin receptors (SSR1 to SSR5) • Somatostatin receptor type 2 (SSR2) is clearly predominant. • These receptors represent the molecular basis for the clinical use of somatostatin analogues in the imaging and treatment of endocrine tumors • 3 somatostatin analogs, OC, TOC and TATE were conjugated to the metal chelator DOTA and labeled with the radiometal 111In, 90Y and 68Ga. • Somatostatin receptor scintigraphy (SRS) had been used for the detection of occult primary tumors and metastatic lesions, and it had been suggested that it should be the first imaging procedure for staging, before CT and MRI. A. Hubalewska-Dydejczyk et al., Eur J Nucl Med Mol Imaging (2006)
  7. 7. Somatostatin and Octreotide: Molecular Characteristics Amino acids essential for receptor binding ala gly cys lys asn phe phe cys ser thr phe thr lys trp phe cys phe thr ol cys thr lys D trp OctreotideHuman somatostatin Harris AG. Drug Invest. 1992;4(suppl 3):1-54.
  8. 8. Tumors with High Expression of SSR • 1. Adrenal medullary tumors (pheochromocytoma, neuroblastoma, ganglioneuroma, paraganglioma) • 2. Gastroenteropancreatic neuroendocrine tumors (formerly termed carcinoid, gastrinoma, glucagonoma, vasoactive intestinal polypeptide-secreting tumor, pancreatic polypeptide- secreting tumor, etc., or nonfunctioning gastroenteropancreatic tumors), • 3. Merkel cell tumor of the skin • 4. Pituitary adenoma • 5. Small-cell lung carcinoma Tumors with Low Expression of SSR 1. Astrocytoma 2. Benign and malignant bone tumors 3. Breast carcinoma 4. Differentiated thyroid carcinoma (papillary, follicular, Hu¨rthle cell) 5. Lymphoma (Hodgkin and non-Hodgkin) 6. Melanoma 7. Meningioma 8. Non–small cell lung carcinoma 9. Prostate carcinoma 10. Renal cell carcinoma 11. Sarcomas Tumors with Variable Expression of SSR (especially Subtype 2) 1. Insulinoma 2. Medullary thyroid carcinoma D. Expression of SSR in Nonneoplastic Processes 1. Autoimmune diseases (e.g., rheumatoid arthritis, Graves’ disease, Graves’ ophthalmopathy) 2. Bacterial pneumonia 3. Cerebrovascular accident 4. Fibrous dysplasia 5. Granulomatous diseases (e.g., tuberculosis, sarcoid) 6. Postradiation inflammation Oncological and non oncological SSR expression
  9. 9. Radionuclide for Somatostatin receptor Imaging SSR Radiotracer Source Injected dose Imaging time Imaging Dosimetry In-111-Octreotide In-111-Lanreotide cyclotron 222 MBq (173 and 247 KeV), 24 P.I(4 and 48 hrs optional) T1/2: 67 h Planner+ SPECT (SPECT/CT) 12 mSv +Auger electrons Tc-99m- Octreotate Tc-99m- Octreotide Tc-99m- depreotide Tc-99m generator 740 MBq 2 and 4 (24 hrs optional) P.I T1/2: 6h Planner+ SPECT (SPECT/CT) 4 mSv 68Ga-DOTANOC; sstr2,3,5 First, 68Ga-DOTATOC, 68Ga-DOTATATE. Recent, sstr2 in 10x Ge68/Ga68 generator 165–243 MBq (mean 202 MBq) After 30-to 60- min uptake period T1/2: 68 minutes PET/CT 3-4 mSv
  10. 10. Results of the clinical application of somatostatin receptor imaging using various ligands in patients with gastroenteropancreatic neuroendocrine tumors
  11. 11. Normal distribution in radio labeled SR analog
  12. 12. Causes of potential misinterpretation of results with octreotide scintigraphy
  13. 13. In-111- OCTREOTIDE IMAGING WHAT IS THE EXPECTED DIAGNOSIS? Paraganglioma PheoCh Neuroblastoma 56 year old female presents with nausea, flushing, and low back pain. No history of hypertension. Blood work revealed elevated levels of norepinehprine, epinephrine dopamine and cathecholamines. ultrasound and CT scan demonstrated a large right suprarenal mass. Plan-obtain octreotide scan to evaluate primary lesion and search for additional lesions. Right adrenal pheochromocytoma
  14. 14. • 65-year-old male who has poorly differentiated neuroendocrine carcinoma of the liver by biopsy. In-111- Octreotide was obtained to evaluate for additional sites of metastatic disease and for assessment of possible primary site of disease 4 hrs WB images 24 hrs WB images Is this a normal octreotide scan? Teaching point Knowing normal biodistribution of In-111 octreotide is very important as it was the key in this case.
  15. 15. 78 years old male Saudi patient with known carcinoid tumor s/p resection from small bowel, mediastinal lymph nodes and recently elevated tumor markers – 5HIAA / 24 h urine = 88 μmol/24 h (normal 10.5–47.2 μmol/24 h) – Serum CEA = 7.2 ug/L (normal 0-3.4 ug/L) Serum CA 19-9 = 55 u/ml (normal 0-34 u/ml) 99mTc-octreotide (Tektrotyd) Scan (1) – Tc-99m Tektrotyd Liver lesions-not on CT Abdominal mesenteric LNs Lt supraclav. and mediastinal LNs
  16. 16. • 62 year old female patient with carcinoid of small bowel, post resection and anastomosis and elevated tumor markers for assessment. • 5HIAA / 24 h urine = 70.7 μmol/24 h (normal 10.5–47.2 μmol/24 h) 99mTc-EDDA/HYNIC-octreotide (Tektrotyd) Scan (2)
  17. 17. Patient presented with metastatic left supraclavicular LN from unknown NET with multiple hepatic metastases seen in CT was investigated with SRS. GASTRINOMA 99mTc-EDDA/HYNIC-octreotide (Tektrotyd) Scan (2) Shah, et al; Indian Journal of Radiology and Imaging November 2011. SPECT/CT improves image interpretation • Identify unsuspected tumor or extent of ca • Differentiate physiologic activity from ca • Significant Change in Management
  18. 18. A metastatic case of small bowel NET treated by Peptide Receptor Radionuclide Therapy (PRRT). T-99m SSR Imaging ordered to assess response to therapy. A) the baseline planar WB image shows uptake in the primary (thin arrow) and multiple hepatic metastasis (thick arrow). (B)WB planar SSTR imaging after 3 cycles of SS therapy show complete regression of the tracer uptake at the primary and the hepatic metastasis indicating the suppression of SSR due to therapy. The patient considered responder and completed further therapy. He was documented to be DF on his last follow-up, 1.5 year post last radioimmunoscintigraphy. Shah, et al; Indian Journal of Radiology and Imaging November 2011.
  19. 19. 68Ga-DOTA-TOC PET/CT A case of tail of Pancreas NET with only metastatic hepatic lesions seen US, CT and MRI. With a permission from Abdullah ALQARNI PSMMC NucMed symposium 2013,
  20. 20. A 55-y-old woman with multiple small liver metastases from pancreatic head NET S/P surgical resection and received 4 cycles of 177Lu-DOTA-TATE 68Ga-DOTATOC PET scan (A) Before SRRT showed multiple small hepatic metastasis. (B) Post therapy scan showed excellent treatment response . (C and D) However, corresponding CT scans initially showed no remarkable change in liver lesions 68Ga-DOTATOC PET scan in treatment monitoring Gabrie et al; J Nucl Med 2009; 50:1427–1434
  21. 21. Baum et al; SNM 2008
  22. 22. Middle age woman with longstanding history of ‘chronic pancreatitis’. At second operation found to have subcentimetre hepatic metastasis with histology demonstrating well- differentiated neuroendocrine tumour. Triple phase CT scan demonstrated no abnormality apart from multiple sclerotic bone lesions considered to be benign bony islands (osteopoikylosis) with prior ‘negative’bone biopsy. GaTate positron emission tomography (PET)/CT scan (MIP) and selected axial PET/CT fusion slices) performed 1 week later demonstrated a pancreatic primary and sub-centimetre liver metastasis (red arrows), and widespread nodal and osseous metastases. The patient subsequently underwent radionuclide therapy with 177lutetium-octreotate. MS Hofman et al. J of Medical Imaging and Rad Onco © 2012 111In-octreotide scan anterior planar and single photon emission tomography/CT (not shown) demonstrated a solitary left supraclavicular nodal abnormality (blue arrow). 111In-octreotide scan68 Ga-DOTATATE
  23. 23. Baum et al; SNM 2008
  24. 24. • MIBG shows the same cellular transport system as norepinephrine, and accumulates in neuroendocrine tumors, mainly in pheochromocytoma, neuroblastoma, and paraganglioma. • MIBG scintigraphy has a limited role in the management of carcinoids and in GEP tumors, while it has found a large application for the diagnosis of neoplasia of sympathoadrenal lineage • 60–70% of carcinoids are visualized using MIBG I-131/I-123 Metaiodobenzylguanidine (MIBG) ANT. POST. Normal MIBG uptake
  25. 25. 50-year-old man with a palpable neck mass, progressive dyspnea, and intermittent episodes of supraventricular tachycardia. Abdominal CT revealed only a 2-cm left adrenal nodule, which was thought to be an incidental finding. (a) Anterior whole-body In-111 pentetreotide image shows the neck mass (arrow) and anterior mediastinal uptake (arrowhead). (b, c) Anterior I-131 MIBG scans of the head (b) and chest (c) show the neck mass (white arrow in b), mediastinal uptake (black arrow in b and c), and a faint focus inferior to the mass (arrowhead). No abnormal uptake was seen in the abdomen and pelvis, including the suprarenal area. Carotid body paraganglioma (glomus tumor) At surgery, the neck mass proved to be a paraganglioma at the carotid bifurcation, with a small satellite lesion adjacent to the trachea corresponding to the faint focus. Mediastinal uptake on all three images represented normal thymic tissue. Intenzo et al; RadioGraphics 2007 Teaching points Paraganglioma is both MIBG and SR avid lesion. -Paraganglioma lighten up more in MIBG than in SRS with more lesions seen in MIBG. Normal thymic tissue can be MIBG and SR positive
  26. 26. What is the differential diagnosis? A case 8-month-old girl who was admitted for URI symptoms. At that time, a right upper quadrant mass was detected on physical examination CT Findings: There is a large, heterogeneously enhancing mass within the right mid and upper abdomen, with several regions of calcification within this mass. Bone Scan: There is uptake of Tc-99m MDP in the CT noted abdominal mass, which extends to the midline I-123 MIBG : Markedly increased MIBG activity is identified in the right paraspinal region in a triangular configuration and fiant focal uptake in the left frontal bone MIR NucMed teaching files, Wash U MO Teaching points The differential diagnosis for retroperitoneal masses in the adrenal/ renal region for children includes Neuroblastoma and Wilm's tumor. -Wilm's tumor typically does not calcify, and would have no uptake on bone scan (due to absent calcification) and no uptake on MIBG. MIBG scintigraphy is more sensitive than bone scan for detection of metastatic disease due to neuroblastoma.
  27. 27. 24 hrs I-123 SPECT/CT 15-1-2013 24 hrs I-123 WB 7-8-2012 A 22 years Saudi female patient Status post resection of left side pheochromocytoma and repair of transposition of great vessels, CT showed stable tiny right adernal nodule and two suspicious hepatic lesions. I- 123 MIBG ordered to R/O recurrence. ADDED VALUE OF SPECT/CT IN NET SCINTIGRAPHY
  28. 28. I-123 MIBG scan Charles et al’ RadioGraphics 2007 MIP of FDG PET scan a) Abdominal MR image shows a 7.5 6.9-cm left adrenal mass (arrow). (b) On an anterior abdominal I-123 MIBG scan (spot view), the mass avidly concentrates radiotracer. (c) PET was performed as a second whole-body survey for metastases Anterior MIP of FDG PET scan shows strongly positive uptake. FDG accumulates in malignant PHEO (sensitivity of 88%) to a greater extent than in benign PHEO (58%). A 78-year-old man with recent onset of hypertension and arrhythmias. The patient underwent a work-up for PHEO, which revealed a high level of plasma norepinephrine along with high urine levels of norepinephrine, dopamine, and metanephrine
  29. 29. Other PET Radiopharmaveuticals for NET Imaging • F-18 FDG (GLUT) • 18F-dihydroxy-phenyl-alanine (18F-DOPA) • 11C-5-hydroxy-tryptophan (11C-5-HTP)
  30. 30. F-18 FDG PET/CT • FDG positron emission tomography (PET) is useful only in patients who are suspected of having aggressive neuroendocrine tumors that are not detected by somatostatin receptor imaging or conventional anatomic imaging.
  31. 31. FDG PET/CTTc-99m octreotide
  32. 32. (A) 68Ga-DOTATATE and (B) 18F-FDG PET/CT images from a patient with well-differentiated (‘typical’) bronchial carcinoid tumor. The primary tumor (left hilum, arrow) is positive for (A) 68Ga-DOTATATE but negative for (B) 18F-FDG. Histology showed that the left lung had postcollapse pneumonitis that was negative for (A) 68Ga-DOTATATE uptake but positive for (B, broken arrow) 18F-FDG. From: Irfan Kayani et al; American Cancer Society 2008 A B
  33. 33. Baum et al; SNM 2008
  34. 34. 18F-dihydroxy-phenyl-alanine (18F-DOPA) & 11C-5-hydroxy-tryptophan (11C-5-HTP) • NET´s belong to the so called amine precursor uptake and decarboxylation (APUD)- omas, ie, they have the capacity for uptake and decarboxylation of amine precursors like 5-hydroxytryptophan (5- HTP) or L-dihydroxyphenylalanine (L-DOPA), and subsequent storage or release of serotonin (5- HT) and dopamine. • Carcinoid tumors of midgut origin, midgut carcinoids (MGC) produce serotonin via the precursors tryptophan and 5-hydroxytryptophan. Serotonin is metabolized to 5-hydroxyindole acetic acid (5- HIAA) and excreted in the urine. • For midgut carcinoids serotonin, urinary-5-HIAA and chromogranin A (CgA) are the main tumor markers. • whereas in foregut carcinoids (bronchial carcinoids and endocrine pancreatic tumors (EPT)) and hindgut carcinoids serotonin production is rare and therefore 5-HIAA is seldom increased.
  35. 35. 11C-HTP PET/CT • Promissing results and high accuracy in pancreatic NET. • Sens. 96% • Superior to 18F-DOPA or Octreotide • HTP PET/CT excellent imaging method in pancreatic islet cell tumors
  36. 36. 11C- 5 hydroxytryptophan Somatostatin RS MEN-1 syndrome and multiple gastrinomas in the pancreas duodenal gastrinoma Patient with biochemical evidence of a gastrinoma and where endoscopic ultrasonography indicated a pathological intraabdominal lesion. Both SRS and CT were negative. 11C-5 HTP positive >>>>> duodenal gastrinoma >>>>>conformed in surgery
  37. 37. 18F-DOPA • Combined PET/CT –Pheochromocytoma lesion based sensitivity – DOPA 93% (vs MIBG P<0.05, CT < 0.001) – 123I-MIBG 76% • In Meddullary Thyroid Carcinoma (MTC) – CT/MRI 64% – DMSA SPECT 19% – FDG PET 30% – DOPA PET 71% – DOPA PET/CT 89% • FDG may detect more dedifferentiated lesions • DOPA detects more differentiated lesions • American Thyroid Association: Calcitonin > 150 pg/mL do 18F-DOPA • In Congenital hyperinsulinism of infancy (CHI): [18F]-DOPA PET should be considered as a primary differential diagnostic tool in infantile hyperinsulinemic hypoglycemia
  38. 38. (18F-FDOPA)  BILATERAL PHEOCHROMOCYTOMAS • Negative in MIBG  INSOLINMA  PET Successful Surgery
  39. 39. 18F-DOPA In MTC
  40. 40. 18F-DOPA In Congenital hyperinsulinism of infancy (CHI) Pancreatic tail focal CHI Pancreatic body focal CHI
  41. 41. 18F-DOPA In monitoring treatment of (CHI)
  42. 42. • (a) 18F-DOPA PET of a 56-year-old female diagnosed with NETof the pancreas with liver metastases. Note the physiological uptake in the gallbladder (Balan 2005). (b) 11C-5-HTP PET indicating more tumour mass and higher number of liver metastasis.
  43. 43. Ga68-peptide-PET or 18F-DOPA: depends on NET subtype • Ambrosini 2008: 68Ga 13/13, DOPA 9/13 - 11 foregut tumors • Haug 2009: 68Ga Sens 96, vs DOPA 56% [n=25] - 11 foregut, 5 unknown, 9 gut tumors • Montraverse EANM 2010: in ileal carcinoid DOPA superior to Ga68-PET Pancreas NET Midgut carcinoid DOPA DOPAGa68-DOTATATE Ga68-DOTATATE
  44. 44. Take Home Message • At this time, no single imaging modality is considered the procedure of choice for neuroendocrine tumor evaluation. • Functional imaging is more sensitive and more specific than anatomical imaging. • Selection of the radiotracer for NET depend on the histological subtypes and location. • SPECT/CT improve image interpretation in gamma emitter STR radionuclide. • Although at present it is established that PET tracers as somatostatin analogues labeled with 68Ga are superior to that of gamma emitting agents as regards sensitivity and accuracy, the latter could still represent an accessible alternative specially when PET technology or PET radiopharmaceuticals are not accessible. • FDG PET/CT has a role in evaluation of aggressive poorly differentiated NET • [18F]-DOPA PET is a promising diagnostic tool in evaluation of NET especially in MTC and CHI. • Ga-68 has a future to be the technetium tracer for the PET.
  45. 45. THANK YOU

×